-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Pfizer announced a new organizational structure adjustment in China
.
According to the announcement information, the new structure includes six independent business units, including hospital emergency, tumor, rare diseases, inflammation and immunity, vaccines, and a broad market, and will be officially effective on December 1 this year.
Among them, it is worth noting that, The broad market team was set up as an independent business unit for the first time
.
In this regard, Pfizer said that it will work to reduce the difference in medical standards between different regions, which fully reflects Pfizer China's emphasis on a broad market, its determination to take root in China and serve China, and its commitment to help a healthy China 2030
.
In fact, Pfizer has a long-term business-oriented management structure in the past.
This management structure is characterized by direct reports from regional business leaders to global business leaders and dotted lines to regional CEOs
.
However, in recent years, as Pfizer merged the consumer business with GSK and the mature medicine business merged with Mylan, a series of strategic adjustments have also accelerated the company's move to a region-oriented management structure
.
Therefore, regarding Pfizer's substantial adjustment of its management structure in China, further strengthening the strategic position of the grassroots market team, and the establishment of a separate market expansion team, the industry generally believes that it will help Pfizer to grasp the extended opportunities in the broad market and combine digital platform services for more Patient
.
In fact, in recent years, China's huge medical market is attracting the attention of more and more multinational pharmaceutical companies
.
But at the same time, the introduction of a series of medical reform documents, especially the volume procurement, is also bringing more changes to the domestic pharmaceutical and medical markets
.
In this context, it is conceivable that multinational pharmaceutical companies have accelerated their domestic strategic layout and personnel adjustments in order to adapt to market development
.
It is understood that in addition to Pfizer this year, many multinational companies are also actively adjusting their corporate structures and have made "big moves" in resources and personnel
.
For example, on September 6, it was reported that AstraZeneca China announced to its employees-AstraZeneca China Rare Diseases Business Department was formally established, and the former head of the Strategic Project Management Office of AstraZeneca China Oncology Business Department, Simeti Wu Yun, Executive Director of Marketing and Sales of Nigeria, served as the head of the rare disease business department, reporting directly to Wang Lei, Executive Vice President of AstraZeneca Global, President of International Business and China
.
In addition, since December 2020, Roche has also begun to break the original product line model and cancel some team sales targets in some areas
.
At the beginning of September this year, Roche Pharmaceuticals China also issued an internal announcement stating that it would add a Chinese product pipeline strategy team
.
At the same time, Ms.
Chen Xingrong, the head of the company's transformation and innovation office, will concurrently serve as the head of the China product pipeline strategy team
.
According to Roche Pharmaceuticals, the establishment of the China Product Pipeline Strategy Team this time is mainly to strengthen China's overall strategic layout, and to work closely with headquarters and all parties in the industry chain to benefit more Chinese patients
.
In addition, AstraZeneca, Merck & Co.
have also adjusted and deployed their domestic businesses
.
The industry believes that the continuous changes in the external environment in recent years, especially in the context of China's new medical reform, such as the implementation of a series of policies such as medical insurance catalog negotiations, volume purchases, and disease-based payment, have continued to put pressure on foreign pharmaceutical companies
.
In this context, in the future, it is expected that more multinational pharmaceutical companies may accelerate the "transformation and upgrade" and seize the domestic market share by actively adjusting their domestic strategic layout
.
.
According to the announcement information, the new structure includes six independent business units, including hospital emergency, tumor, rare diseases, inflammation and immunity, vaccines, and a broad market, and will be officially effective on December 1 this year.
Among them, it is worth noting that, The broad market team was set up as an independent business unit for the first time
.
In this regard, Pfizer said that it will work to reduce the difference in medical standards between different regions, which fully reflects Pfizer China's emphasis on a broad market, its determination to take root in China and serve China, and its commitment to help a healthy China 2030
.
In fact, Pfizer has a long-term business-oriented management structure in the past.
This management structure is characterized by direct reports from regional business leaders to global business leaders and dotted lines to regional CEOs
.
However, in recent years, as Pfizer merged the consumer business with GSK and the mature medicine business merged with Mylan, a series of strategic adjustments have also accelerated the company's move to a region-oriented management structure
.
Therefore, regarding Pfizer's substantial adjustment of its management structure in China, further strengthening the strategic position of the grassroots market team, and the establishment of a separate market expansion team, the industry generally believes that it will help Pfizer to grasp the extended opportunities in the broad market and combine digital platform services for more Patient
.
In fact, in recent years, China's huge medical market is attracting the attention of more and more multinational pharmaceutical companies
.
But at the same time, the introduction of a series of medical reform documents, especially the volume procurement, is also bringing more changes to the domestic pharmaceutical and medical markets
.
In this context, it is conceivable that multinational pharmaceutical companies have accelerated their domestic strategic layout and personnel adjustments in order to adapt to market development
.
It is understood that in addition to Pfizer this year, many multinational companies are also actively adjusting their corporate structures and have made "big moves" in resources and personnel
.
For example, on September 6, it was reported that AstraZeneca China announced to its employees-AstraZeneca China Rare Diseases Business Department was formally established, and the former head of the Strategic Project Management Office of AstraZeneca China Oncology Business Department, Simeti Wu Yun, Executive Director of Marketing and Sales of Nigeria, served as the head of the rare disease business department, reporting directly to Wang Lei, Executive Vice President of AstraZeneca Global, President of International Business and China
.
In addition, since December 2020, Roche has also begun to break the original product line model and cancel some team sales targets in some areas
.
At the beginning of September this year, Roche Pharmaceuticals China also issued an internal announcement stating that it would add a Chinese product pipeline strategy team
.
At the same time, Ms.
Chen Xingrong, the head of the company's transformation and innovation office, will concurrently serve as the head of the China product pipeline strategy team
.
According to Roche Pharmaceuticals, the establishment of the China Product Pipeline Strategy Team this time is mainly to strengthen China's overall strategic layout, and to work closely with headquarters and all parties in the industry chain to benefit more Chinese patients
.
In addition, AstraZeneca, Merck & Co.
have also adjusted and deployed their domestic businesses
.
The industry believes that the continuous changes in the external environment in recent years, especially in the context of China's new medical reform, such as the implementation of a series of policies such as medical insurance catalog negotiations, volume purchases, and disease-based payment, have continued to put pressure on foreign pharmaceutical companies
.
In this context, in the future, it is expected that more multinational pharmaceutical companies may accelerate the "transformation and upgrade" and seize the domestic market share by actively adjusting their domestic strategic layout
.
